QNRX QNRX
Company Profile ↓Company Overview
QNRX (QNRX) is a publicly traded company listed on with a market capitalization of $229.17M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -34.73% |
| 6 Months: | -41.97% |
| 3 Months: | -30.74% |
| 1 Month: | -8.96% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 80.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 3.96M | 3.79M | 4.02M | 4.52M | 5.13M |
| Operating Income | - | - | - | - | - | - | - | - | - | -3.96M | -3.79M | -4.02M | -4.52M | -5.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | -3.93M | -3.77M | -3.99M | -4.50M | -5.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -3.81M | -3.70M | -3.95M | -4.35M | -5.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.68M | -2.67M | -3.03M | -2.60M | -2.11M | -1.93M | -2.33M | -1.97M | -2.35M | -3.81M | -3.70M | -3.95M | -4.35M | -5.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -6.50 | -6.28 | -6.71 | -1.74 | -1.77 |
| R&D Expense | 587.57K | 726.69K | 745.51K | 1.09M | 625.10K | 758.76K | 885.30K | 587.50K | 1.08M | 2.37M | 2.05M | 2.28M | - | 3.43M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 9.26M | 9.38M | 9.53M | 16.29M |
| Operating Income | - | -9.26M | -9.38M | -9.53M | -16.29M |
| EBITDA | - | -8.56M | -9.27M | -9.43M | -16.19M |
| Interest Expense | 1.09M | 714.08K | 0 | - | - |
| Pretax Income | - | -9.38M | -8.69M | -8.96M | -15.80M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -9.38M | -8.69M | -8.96M | -15.80M |
| Diluted EPS | - | -1,638.23 | -337.47 | -66.85 | -14.80 |
| R&D Expense | 1.56M | 2.67M | 3.31M | 3.60M | 9.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 14.46M | 12.17M | 15.71M | 20.39M |
| Current Assets | - | - | 13.37M | 11.29M | 14.93M | 20.01M |
| Cash & Equivalents | - | - | 2.86M | 2.40M | 3.62M | 3.82M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Total Liabilities | - | - | 7.05M | 6.51M | 6.50M | 7.27M |
| Current Liabilities | - | - | 3.53M | 3.58M | 4.18M | 5.55M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - |
| Total Equity | -6.61M | - | 7.41M | 5.66M | 9.20M | 13.12M |
| Shares Outstanding | - | - | 403.88K | 987.22K | 8.95M | 52.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.48M | -7.86M | -7.86M | -13.54M |
| Investing Cash Flow | - | -10.15M | 2.19M | -1.89M | -4.28M |
| Financing Cash Flow | - | 14.01M | 5.22M | 10.97M | 18.01M |
| Capital Expenditure | -625.00K | -250.00K | - | - | - |
| Free Cash Flow | - | -8.73M | -7.86M | -7.86M | -13.54M |
| Net Change in Cash | - | -4.62M | -459.43K | 1.22M | 195.37K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -126.7% | -153.4% | -97.4% | -120.5% |
| ROCE % | - | -84.7% | -109.2% | -82.7% | -109.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QNRX
FDA conditionally approves Quoin's QYLEKI name for rare skin drug - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPSW44NG5KUzItb2hEYURMZ1JVQjhKTGNiZzBjR1RvWVJJajR4ZGhyZXlDQ3Fla0FxSGxpSTlNVUlaa1JpbEstekVDME1kejR4ck83YkRQSVA5SkxtYUQ1R2V2SGlwLVJWajlZM09yeHJHYm5VNWN0Mmt3ZmlmVnJTV3JpZTdWWVZqd2JkaV…
QNRX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE4ycFJQcjcxRzJKem5vRzZ5UFhCZ0pOX2RfMTZIQUFTLWlTSEtuWmNSYmdIa19RY0lGZXRtbkE0ZTdCSlVBaWtsSFFNM3hsMjRCRWY1bldfYmozMUgzdHNqRnFTQmM1MWtmVnRyZzN1WFVyY0pkbXJXdDNn?oc=5" target="_blank">QNR…
Quoin Pharmaceuticals Garners Buzz After FDA’s Comments On Netherton Syndrome Lead Drug - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYVQ1Zkt6eGNxM3RvN1A2bHo0SmRVVXppU0YxeGt6YkNhWEl3TkxOM2FRYXZFSlY3bXAzOUN6ZlVXOVh3S1p3MlIxdVBBUkdfUlB2U0l6T0hoa2g0SGdQRG1FWElvRndya2F3bFYwZDdkdldLeFZDWUc0RDYtWmY0SU1udUxYMHBaNHZrQW…
QNRX|Quoin Pharmaceuticals Ltd|Price:4.450|Chg%:+0.110 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE52Z19VWkRyRnR1ZXM3dmd0S1JRYlY5Skp4bi1PYVdxbklXNzBJZW9ZNDFsTnlRSTZnbVVqeEh2TGFQNWNNVDNrdkVScUJOM0N4MWpwc2kwSEQtQQ?oc=5" target="_blank">QNRX|Quoin Pharmaceuticals Ltd|Price:4.450|Ch…
Market Sentiment Around Loss-Making Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNdV9VV0NEMTVXdTYtWVRNTnNjOVJTcklEWC1pa1Q4WWRwVFVyVXpNZFVKVzlrZUpsd1hoVlAzOE9rLUNkRlBhWS15YjJZVGFtVllQcnNXdkZVSEpORjRXN2JMSWJjWVhnY2doVWhGTlJfcmlBYlJ1Z1pUZGg5Q1ItaXZJbzFVaDhBdFFpcE…
Quoin Pharmaceuticals (NASDAQ:QNRX) gets FDA clearance for Phase 2 study in ultra-rare peeling skin syndrome - Kalkine
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNOVVnWlZxTG1FRVVGdW9YT2wyMzFfenh5N1ljdE11b0NFVm5sMXFNM2dPajVzLXVybXQzcUdlbXk2Q2tVdUFYVkhYSllPcEo4bzhmYnE2YWdWRmE2QUpaeHBVdHQweUY2ZGZkYWl0ZWtoQlc0bDFnUlVtZGd3cUxOYmZDanFlWjBFa0N2QT…
QNRX — Frequently Asked Questions
What is the current share price of QNRX?
As of 2026-08-05 17:25 PDT, QNRX trades at $4.37 on NASDAQ/NYSE. Its 52-week range is $3.25 to $22.30.
What is the market capitalisation of QNRX?
QNRX has a market capitalisation of $229.17M on NASDAQ/NYSE.
What is the P/E ratio of QNRX?
QNRX trades at a trailing price-to-earnings (P/E) ratio of -0.30. Its price-to-book (P/B) ratio is 17.47.
What is the return on equity (ROE) of QNRX?
QNRX has a return on equity (ROE) of -120.46%. Its return on capital employed (ROCE) is -109.75%.
Is QNRX a good stock to buy?
This page provides a data-driven analysis of QNRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.